Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina, GreeceAbstract: Parkinson’s disease therapy is still focused on the use of l-3,4-dihydroxyphenylalanine (levodopa or l-dopa) for the symptomatic treatment of the main clinical features of t...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/748b0b5b4e2c4f8ea983c472fcb6463b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:748b0b5b4e2c4f8ea983c472fcb6463b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:748b0b5b4e2c4f8ea983c472fcb6463b2021-12-02T04:58:17ZLevodopa-induced dyskinesias in Parkinson’s disease: emerging treatments1176-63281178-2021https://doaj.org/article/748b0b5b4e2c4f8ea983c472fcb6463b2013-10-01T00:00:00Zhttp://www.dovepress.com/levodopa-induced-dyskinesias-in-parkinsonrsquos-disease-emerging-treat-a14759https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina, GreeceAbstract: Parkinson’s disease therapy is still focused on the use of l-3,4-dihydroxyphenylalanine (levodopa or l-dopa) for the symptomatic treatment of the main clinical features of the disease, despite intensive pharmacological research in the last few decades. However, regardless of its effectiveness, the long-term use of levodopa causes, in combination with disease progression, the development of motor complications termed levodopa-induced dyskinesias (LIDs). LIDs are the result of profound modifications in the functional organization of the basal ganglia circuitry, possibly related to the chronic and pulsatile stimulation of striatal dopaminergic receptors by levodopa. Hence, for decades the key feature of a potentially effective agent against LIDs has been its ability to ensure more continuous dopaminergic stimulation in the brain. The growing knowledge regarding the pathophysiology of LIDs and the increasing evidence on involvement of nondopaminergic systems raises the possibility of more promising therapeutic approaches in the future. In the current review, we focus on novel therapies for LIDs in Parkinson’s disease, based mainly on agents that interfere with glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission that are currently in testing or clinical development.Keywords: motor fluctuations, dopaminergic/nondopaminergic systems, pharmacotherapyBargiotas PKonitsiotis SDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1605-1617 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Bargiotas P Konitsiotis S Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments |
| description |
Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina, GreeceAbstract: Parkinson’s disease therapy is still focused on the use of l-3,4-dihydroxyphenylalanine (levodopa or l-dopa) for the symptomatic treatment of the main clinical features of the disease, despite intensive pharmacological research in the last few decades. However, regardless of its effectiveness, the long-term use of levodopa causes, in combination with disease progression, the development of motor complications termed levodopa-induced dyskinesias (LIDs). LIDs are the result of profound modifications in the functional organization of the basal ganglia circuitry, possibly related to the chronic and pulsatile stimulation of striatal dopaminergic receptors by levodopa. Hence, for decades the key feature of a potentially effective agent against LIDs has been its ability to ensure more continuous dopaminergic stimulation in the brain. The growing knowledge regarding the pathophysiology of LIDs and the increasing evidence on involvement of nondopaminergic systems raises the possibility of more promising therapeutic approaches in the future. In the current review, we focus on novel therapies for LIDs in Parkinson’s disease, based mainly on agents that interfere with glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission that are currently in testing or clinical development.Keywords: motor fluctuations, dopaminergic/nondopaminergic systems, pharmacotherapy |
| format |
article |
| author |
Bargiotas P Konitsiotis S |
| author_facet |
Bargiotas P Konitsiotis S |
| author_sort |
Bargiotas P |
| title |
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments |
| title_short |
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments |
| title_full |
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments |
| title_fullStr |
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments |
| title_full_unstemmed |
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments |
| title_sort |
levodopa-induced dyskinesias in parkinson’s disease: emerging treatments |
| publisher |
Dove Medical Press |
| publishDate |
2013 |
| url |
https://doaj.org/article/748b0b5b4e2c4f8ea983c472fcb6463b |
| work_keys_str_mv |
AT bargiotasp levodopainduceddyskinesiasinparkinsonrsquosdiseaseemergingtreatments AT konitsiotiss levodopainduceddyskinesiasinparkinsonrsquosdiseaseemergingtreatments |
| _version_ |
1718400959764234240 |